Analysis reveals alternative splicing influences tumor immune microenvironment and identifies prognostic biomarkers.
Alternative splicing (AS) generates diverse mRNA isoforms and plays a key role in cancer. Using Drosophila homologous genes, this study identified prognostic AS events across pan-cancer via Cox regression and constructed robust prognostic signatures validated by survival and ROC analyses. AS was shown to significantly influence the tumor immune microenvironment and immunotherapy response. COL1A1 emerged as a strong pan-cancer prognostic factor. Splicing factor regulatory networks and Mendelian randomization analyses further revealed genes associated with tumor development, highlighting AS as a valuable source of prognostic biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: